UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.65 Million Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 10.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 137,447 shares of the company’s stock after selling 15,913 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.16% of Syndax Pharmaceuticals worth $2,646,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in Syndax Pharmaceuticals during the second quarter worth $637,000. Assenagon Asset Management S.A. lifted its stake in Syndax Pharmaceuticals by 54.3% during the 2nd quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company’s stock valued at $8,806,000 after acquiring an additional 151,021 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Syndax Pharmaceuticals by 18.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 291,826 shares of the company’s stock worth $5,991,000 after acquiring an additional 46,463 shares during the last quarter. Peregrine Capital Management LLC grew its stake in shares of Syndax Pharmaceuticals by 1.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 198,659 shares of the company’s stock worth $4,078,000 after acquiring an additional 2,580 shares in the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth $33,000.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. StockNews.com cut shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. JPMorgan Chase & Co. increased their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. The Goldman Sachs Group lifted their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Finally, UBS Group assumed coverage on Syndax Pharmaceuticals in a research note on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Price Performance

Shares of SNDX opened at $13.93 on Friday. Syndax Pharmaceuticals, Inc. has a 1 year low of $13.26 and a 1 year high of $25.34. The stock’s fifty day moving average price is $17.81 and its two-hundred day moving average price is $19.46. The firm has a market cap of $1.19 billion, a PE ratio of -3.84 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the firm posted ($0.73) earnings per share. Sell-side analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current fiscal year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).